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Abstract
Background: Besides clinical stage and Gleason score, risk-stratification of prostate cancer in the pretherapeutic
setting mainly relies on the serum PSA level. Yet, this is associated with many uncertainties. With regard to therapy
decision-making, additional markers are needed to allow an exact risk prediction. Eukaryotic translation elongation
factor 1 alpha 2 (EEF1A2) was previously suggested as driver of tumor progression and potential biomarker. In the
present study its functional and prognostic relevance in prostate cancer was investigated.
Methods: EEF1A2 expression was analyzed in two cohorts of patients (n = 40 and n = 59) with localized PCa.
Additionally data from two large expression dataset (MSKCC, Cell, 2010 with n = 131 localized, n = 19 metastatic
PCa and TCGA provisional data, n = 499) of PCa patients were reanalyzed. The expression of EEF1A2 was correlated
with histopathology features and biochemical recurrence (BCR). To evaluate the influence of EEF1A2 on
proliferation and migration of metastatic PC3 cells, siRNA interference was used. Statistical significance was tested
with t-test, Mann-Whitney-test, Pearson correlation and log-rank test.
Results: qRT-PCR revealed EEF1A2 to be significantly overexpressed in PCa tissue, with an increase according to
tumor stage in one cohort (p = 0.0443). In silico analyses in the MSKCC cohort confirmed the overexpression of
EEF1A2 in localized PCa with high Gleason score (p = 0.0142) and in metastatic lesions (p = 0.0038). Patients with
EEF1A2 overexpression had a significantly shorter BCR-free survival (p = 0.0028). EEF1A2 expression was not
correlated with serum PSA levels. Similar results were seen in the TCGA cohort, where EEF1A2 overexpression only
occurred in tumors with Gleason 7 or higher. Patients with elevated EEF1A2 expression had a significantly shorter
BCR-free survival (p = 0.043). EEF1A2 knockdown significantly impaired the migration, but not the proliferation of
metastatic PC3 cells.
Conclusion: The overexpression of EEF1A2 is a frequent event in localized PCa and is associated with
histopathology features and a shorter biochemical recurrence-free survival. Due to its independence from serum
PSA levels, EEF1A2 could serve as valuable biomarker in risk-stratification of localized PCa.
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Background
In industrialized countries prostate cancer (PCa) is the
cancer entity with the highest incidence in men. Though
most tumors can be cured in early stages or are insignifi-
cant, without need for any treatment at all, around the
world over 250,000 patients die from PCa per year [1].
Due to an increasing awareness, PCa screening has
become more frequent throughout the last decades. Be-
sides digital rectal exam, prostate specific antigen (PSA) is
the current number one screening tool for PCa. But its
value is debated controversially [2], due to limited PCa spe-
cificity and imprecise prediction of PCa aggressiveness [3].
Mixed models implementing PSA level, biopsy Gleason
grade and clinical stage are typically utilized to estimate
the individual risk for aggressive PCa with rapid progres-
sion along with early metastasization and – together with
patient age and risk factors – lead to therapy decision in
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order to avoid overtreatment by treating only relevant
carcinomas [4].
Since these estimations are still imprecise, further
markers, either blood- or urine-based or derived from
biopsy tissue samples, are needed to specify the individ-
ual patient’s risk and to facilitate therapy decision-
making. Yet, PCa markers intensively studied during the
last decade (e.g. genetic markers like the fusion gene
TMPRSS2:ERG, circulating tumor cells or urine PCA3
test) are not used in clinical routine [3, 5, 6].
EEF1A2 (eukaryotic translation elongation factor 1
alpha 2) is part of a complex that enzymatically de-
livers aminoacyl tRNAs to the ribosome and is mainly
expressed in brain, heart and skeletal muscles [7]. In
general it is reported to favor oncogenesis by stimulating
the phospholipid signaling and the Akt-dependent cell mi-
gration [8]. Besides its role in cancer, EEF1A2 mutations
are associated with characteristic facial features, intellec-
tual disability, autistic behavior and epilepsy [9].
There is also evidence, that EEF1A2 expression is pre-
dictive for patient outcome in various epithelial cancer
entities [10–12]. In PCa one study found the more ubi-
quitously expressed isoform EEF1A1 to be overexpressed
in peri-metastatic osteoblasts in PCa bone metastasis,
compared to normal osteoblasts [13]. Another study
found an overexpression of EEF1A2 in PCa tissue com-
pared to matched benign tissue in a small preliminary
cohort [14]. In the same study the authors could show an
overexpression of EEF1A2 to inhibit apoptosis in metastatic
PCa cells. Therefore they claimed EEF1A2 to be a hallmark
for PCa progression. The impact of EEF1A2 expression –
both on the mRNA and on the protein level – on clinical
outcome has not been investigated, yet.
To validate recent findings about EEF1A2 overexpres-
sion in PCa on the mRNA level, sensitive qRT-PCR
techniques were used on two independent cohorts of pa-
tients with localized PCa. Subsequent in silico analysis of
RNA expression datasets served for validation. To gain
further insight into the biological function of EEF1A2 in
PCa siRNA interference experiments were conducted in
vitro.
Methods
Cohorts and patient samples
qRT-PCR was used to asses EEF1A2 RNA expression in
a cDNA array (Origene, Rockville, MD, USA; n = 40
PCa patients and n = 8 benign control samples). Patient
characteristics of this cohort are shown in Table 1.
To further correlate EEF1A2 expression with clinical
follow up data, a cohort of 59 patients who underwent
radical prostatectomy in the Department of Urology of
the Mannheim Medical Center between 1998 and 2001
was analyzed. Patient data of this cohort is given in Table 2.
Prostate tissue specimens from patients who underwent
cystoprostatecomy or transurethral resection of the pros-
tate, with histologically proven tumor-free prostate, served
as controls. All experiments conducted in this retrospect-
ive analysis were in accordance with the institutional
ethics review board (ethics approval 2013-845R-MA).
RNA-extraction, cDNA-synthesis and qRT-PCR from
patient samples
Sections of tumor-bearing or tumor-free FFPE prostate
tissue specimens were stained with hematoxylin and eosin
and reviewed by a trained pathologist. Areas with at least
70% of tumor or tumor-free areas from control patients
were marked and macrodissected from subsequent un-
stained 10 μm sections. RNA was extracted using the
XTRAKT FFPE kit (Stratifyer, Cologne, Germany), as rec-
ommended by the manufacturer. In brief 150 μl of lysis
buffer were added to the tissue sample and incubated
for 30 min at 80 °C while shaking. After cooling down
to 65 °C 50 μl of proteinase K (Roche) were added and
incubated for 30 min at 65 °C while shaking. Subse-
quently 800 μl of MagiX-RNA buffer and 40 μl of
MagiX-RNA beads were added and incubated at room
temperature for 15 min while shaking. The mixed sam-
ples were put on a magnetic rack and washed three
times. Finally the RNA was eluted in 100 μl of elution
buffer. RNA samples were stored at −80 °C.
Table 1 Patient characteristics of the cDNA Array purchased
from Origene
Parameter n
Patients with PCa 40 (mean age 62.8 ± 8.2)
T stage
T1 –
T2 22
T3 12
T4 –
n/a 6
N stage
N0 20
N1 2
Nx 18
Gleason score
5 2
6 8
7a 14
7b 8
8 3
9 4
n.a. 1
Control patients 8 (64.0 ± 10.9)
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To receive a greater yield of target specific transcripts
and to reduce contamination with other amplified cDNA
sequences, we used a multiplexed specific cDNA synthe-
sis with equimolar pooling of transcript specific reverse
PCR primers (primer sequences see below). Superscript
III (Life technologies) was used as reverse transcriptase
at 55 °C for 120 min, followed by an incubation at 70 °C
for 15 min. cDNA was immediately used for qRT-PCR
or stored at −20 °C.
In the cDNA array the expression of EEF1A2 was deter-
mined in relation to the housekeeping gene Calmodulin 2
(CALM2). Intron spanning primer pairs (CALM2: forward
GAGCGAGCTGAGTGGTTGTG reverse AGTCAGTTG
GTCAGCCATGCT amplicon length 72 nt; EEF1A2: for-
ward GGACCATTGAGAAGTTCGAGA, reverse AGCAC
CCAGGCATACTTGAA, amplicon length 70 nt) compat-
ible with the Universal Probe library (Roche Diagnostics)
were designed using the primer3 algorithm [15]. In brief
10 μl of TaqMan Fast Universal PCR Mastermix (Life tech-
nologies), 0.75 μl of forward and reverse primer each
(300 nM) (MWG Eurofins, Ebersberg, Germany) 0.5 μl of
PCR probe (200 nM) (Roche Diagnostics) and 6 μl of
nuclease free H2O were added to 2 μl of cDNA template
each. Subsequently 40 cycles of amplification with 1 s of
95 °C and 20 s of 60 °C were conducted on a Step One Plus
qRT-PCR cycler (Applied Biosystems, Waltham, MA,
USA). To allow a higher input of cDNA, the volume of
primers was halved for qRT-PCR analysis of the Mannheim
cohort. RNA-expression was calculated with the 2(−ΔΔcT)-
method [16].
Datamining and in silico validation
From the online platform CBioPortal [17] RNA expression
data (z-score normalized) of two datasets also comprising
clinical follow-up were downloaded: The MSKCC dataset
consists of 131 primary an 19 metastatic tumor samples
(Taylor et al., Cancer Cell, 2010) [18]. The TCGA (The
Cancer Genome Atlas) dataset includes expression data of
499 primary PCa samples. EEF1A2 RNA expression was
stratified by tumor characteristics and correlated with
BCR-free (biochemical recurrence) survival and serum
PSA levels.
Cell culture, siRNA knockdown and knockdown validation
Human PC3 metastatic PCa cells were obtained from
ATCC (Wesel, Germany) and grown under standard con-
ditions in DMEM (Life Technologies, Carlsbad, CA, USA)
supplemented with 10% FCS (Sigma Aldrich, St. Louis,
LA, USA). siGENOME pooled and individual siRNAs
against EEF1A2 (No 1 GTACAAGATTGGCGGCATT,
No 2 TCAAGAAGATCGGCTACAA, No 3 CTACAAAT
GCGGAGGTATT, No 4 ATGCGGAGGTATTGACAAA)
were transfected using Dharmafect I transfection reagent
(Dharmacon, Lafayette, CO, USA). Dharmacon non-
targeting siRNA were used as negative control. Briefly
cells were detached, harvested, spun down and diluted to
the desired concentration. Meanwhile siRNAs were di-
luted to a target concentration of 30nMol in pure RPMI
(Life Technologies) and incubated for 10 min at room
temperature. Dharmafect I was diluted 1:1000 in RPMI.
After 10 min diluted siRNA and transfection reagent were
mixed 1:1 and again incubated at room temperature for
30 min. Hereafter cell suspension was added to the trans-
fection mix 3:1 and incubated at 37 °C.
qRT-PCR was conducted to validate knockdown of
EEF1A2. RNA-extraction was performed using the
RNeasy Mini Kit (Qiagen, Hilden, Germany) as recom-
mended by the manufacturer. cDNA-Synthesis was per-
formed as described previously [19]: in brief 40 μl of
diluted RNA were mixed with 4 μl of 5 mg/ml pdN6
random primers, 4 μl of 10 mM dNTP Mix, 16 μl of 5×
M-MLV buffer, 8 μl of 0.1 M RNase inhibitor, 4 μl of
0.1 M DTT and 4 μl of M-MLV reverse transcriptase (all
from Roche Diagnostics, Basel, Switzerland). After an
incubation for 2 h at 37 °C and a deactivation step of
5 min at 65 °C, cDNA was directly used for qRT-PCR or
stored at −20 °C. qRT-PCR analyses were performed
Table 2 Patient characteristics of the cohort recruited in Mannheim
Parameter n
Patients with PCa 59 (mean age 62.9 ± 6.9)
T stage
T1 –
T2 23
T3 33
T4 3
N stage
N1 5
N0 47
Nx 7
Gleason score
3 1
4 0
5 10
6 15
7a 15
7b 4
8 5
9 3
10 2
n.a. due to prior antihormonal therapy 4
average serum PSA level 13.3 ng/ml (2.8–73.0 ng/ml)
Control patients 15 (mean age 67.2 ± 11.3)
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using the same primers, reagents and PCR protocol as
described for tissue sample analyses.
Proliferation assay
PC3 cells were seeded and transfected following the
protocol described above in 96-well plates (4500 cells in
100 μl/well). After 24 h the supernatant was replaced by
100 μl of fresh growth medium (DMEM with 10% FCS).
After further 24, 48 and 72 h of incubation 10 μl of
MTT-reagent (Promega, Mannheim, Germany) were
added to each well and incubated for 3 h at 37 °C.
Absorption measurement at 570 nm was done with an
Infinite M1000 Pro plate reader (Tecan, Männerdorf,
Switzerland).
Scratch assay
Using the same transfection protocol, PC3 cells were
seeded in 24-well plates (250,000 cells in 1 ml of DMEM
with 10% FCS per well). The medium was changed 24 h
after transfection. Again 24 h later a defined scratch was
introduced in the center of the well with a sterile 200 μl
pipette tip and the medium was changed again. The
scratch was photographed at 10× magnification. Subse-
quent images were acquired after further 24, 48 and
72 h. The cell free space in the scratch area was calcu-
lated with the open source software tscratch (ETH Zür-
ich, Switzerland) [20]. The free area 24, 48 and 72 h
after scratch were normalized to the initial scratch size.
Statistics
Statistical calculations were performed using Prism 6
(Graphpad, La Jolla, USA). Mann-Whitney-Test was used
for calculation of inter-group expression changes in pa-
tient cohorts analyzed with qRT-PCR and in silico data.
Outcome correlations were done using the log-rank test.
Correlations with the PSA serum level were performed
using Pearson correlation. Parametric t-test was used for
in vitro assays. P-values ≤0.05 were deemed significant.
Results
qRT-PCR analysis indicates EEF1A2 overexpression in PCa
patients
To investigate the expression of EEF1A2 in PCa qRT-
PCR expression analyses in a cDNA array of 40 patients
with localized PCa were performed. Compared to
benign tissue samples EEF1A2 was overexpressed 6.76-
fold in T2 tumors (p = 0.006) and 16.6-fold in T3
tumors (p = 0.0011) (Fig. 1a). The expression was also
significantly higher in T3 compared to T2 tumors
(p = 0.0443). Similar results were seen after stratifica-
tion for Gleason grade (Fig. 1b). Tumors with a
Gleason score ≤ 7a had a 7.22-fold higher expression of
EEF1A2 (p = 0.0064). In tumors with Gleason ≥7b a
15.09-fold higher expression was seen (p = 0.0004).
Though EEF1A2 expression was higher in tumors with
higher Gleason score, no significant difference was seen
between tumors with Gleason score ≤ 7a and ≥7b
(p = 0.0541).
Since the analyzed cDNA array did not provide clinical
follow-up data, the expression of EEF1A2 was further
evaluated in a cohort of 59 patients treated with radical
prostatectomy in the Mannheim Medical Center.
EEF1A2 was significantly overexpressed in these tumor
samples (Fig. 2a). In T2 tumors EEF1A2 was 2.16-fold
overexpressed compared to benign controls (p = 0.0277).
In T3/4 tumors a 2.23-fold overexpression was observed
(p = 0.0325). In this dataset no significant difference in
expression was seen between T2 tumors and locally
advanced tumors.
EEF1A2 expression did not correlate with the serum
PSA level (r = −0.02058; p = 0.8771). Kaplan-Meier
analysis revealed a slightly shorter recurrence-free
survival of patients with high EEF1A2 expression
(mean follow-up 67.5 months, ± 51.2 months, Fig. 2b).
Yet, log-rank test showed this difference not to be
significant (p = 0.14). Taken together, these results
point to a potential relevance of EEF1A2 risk predictor in
localized PCa.
a b
Fig. 1 qRT-PCR analysis in a panel of 40 PCa patients showed an overexpression of EEF1A2 in localized tumor samples. a) EEF1A2 expression was
significantly dependent of tumor stage. b) The averages expression was higher in tumors with a Gleason score ≥ 7b, but this difference did not
reach significance
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In silico analyses reveal EEF1A2 as outcome predictor in
localized PCa
To validate the expression of EEF1A2 in large cohorts of
PCa patients, in silico analyses on the RNA expression
microarray dataset by Taylor et al. and on the RNA
sequencing data of the TCGA cohort were conducted. In
the Taylor et al. dataset 16.8% of patients with localized
PCa had a z-score ≥ 2, compared to benign controls
(Fig. 3a). In metastatic tumor samples EEF1A2 overex-
pression was found in 52.6% of the patients. The highest
expression was seen in PCa metastases (p = 0.0038 when
compared with Gleason 6 localized tumors; Fig. 3b).
Focusing on primary tumors, overexpression of EEF1A2
was a rare event in Gleason 6 tumors (2/41, 4.9%), and
rather seldom in Gleason 7 tumors (13/74, 17.6%). Among
Gleason 8/9 tumors, 7 out of 15 (46.7%) had an EEF1A2
z-score > 2. In line with the qRT-PCR data presented here,
this indicated a higher expression of EEF1A2 in more
aggressive tumors (p = 0.0142 for Gleason 8/9 tumors vs.
Gleason 6 tumors). Pearson correlation of EEF1A2 with
the serum PSA levels at the time of surgery again showed
no correlation (r = 0.1590; p = 0.0708).
Then EEF1A2 expression in primary tumors was cor-
related with patient outcome. Interestingly patients with
an expression z-score of EEF1A2 ≥ 2 had a significantly
shortened BCR-free survival compared to patients with-
out EEF1A2 overexpression (p = 0.0028, mean follow-up
48.5 months, ± 29.6 months, Fig. 3c).
a b
Fig. 2 a) In a cohort of 59 patients, undergoing radical prostatectomy EEF1A2 was overexpressed in PCa. There was no significant difference
between tumor stages. b) Patients with high EEF1A2 expression in the primary tumor in tendency showed a shorter recurrence-free survival. Yet,
log-rank test showed this difference not to be significant
a
b c
Fig. 3 In silico validation of EEF1A2 a) Reanalysis of the microarray dataset by Taylor et al. revealed EEF1A2 to be overexpressed in 16.9% of
localized PCA and in 52.6% of metastatic PCa (dashed line indicates an expression z-score of 2 compared to benign tissue). b) EEF1A2 overexpression
was grade dependent in localized PCa and highest in metastases. c) Localized tumors with high EEF1A2 expression (indicated by a red square in b)
had a significantly shorter biochemical recurrence-free survival
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In the TCGA cohort (n = 499) there was no significant
difference in the average expression of EEF1A2 accord-
ing to the Gleason Score (Fig. 4a). Yet, only tumors with
a Gleason Score of 7 or higher showed an overexpres-
sion of EEF1A2 (z-score ≥ 2). Tumors with an elevated
EEF1A2 expression had a significantly shorter BCR-free
survival (p = 0.043; Fig. 4b). The serum PSA levels of
the patients in this cohort are not available and could
therefore not be correlated with the EEF1A expression.
EEF1A2 is functionally involved in PCa migration but not
in proliferation
To get a first insight into the function of EEF1A2 in
PCa, transient transfection experiments were conducted
in metastatic PC3 cells. qRT-PCR verified a strong
knockdown effect for all used siRNAs (Fig. 5a). For
further experiments siRNA No 3, which produced the
strongest knockdown, was used.
In the MTT assay knockdown of EEF1A did not lead
to a significant alteration of PC3 cell proliferation
(Fig. 5b). By using scratch wound healing assay the influ-
ence of EEF1A2 knockdown on PC3 cell migration was
studied. A significant reduction of migration in cells
with EEF1A2 knockdown was observed (p = 0.035).
After 24 h, 55.6% of the initial scratch area were covered
by control-transfected cells, whereas only 44.7% were
covered in EEF1A2-knockdown cells (Fig. 5c).
Discussion
The study aimed to determine the EEF1A2 expression in
PCa tissue, to test for its potential relevance as risk pre-
dictor in localized PCa and to gain insight into its func-
tional role of in PCa.
EEF1A2 was overexpressed in localized PCa with a
stage-dependent increase in one of the two cohorts
tested with qRT-PCR. In silico analyses of one Taylor et
al. dataset confirmed the overexpression of EEF1A2 in
aggressive localized PCa. The expression was dependent
of the Gleason Score and patients with a high expression
in localized PCa had a significantly shorter BCR-free
survival. In the TCGA dataset EEF1A2 overexpression
only occurred in tumors with a Gleason Score of 7 or
higher and again tumors with an elevated EEF1A2
expression had a significantly shorter BCR-free survival.
qRT-PCR results also point to a potential association
with recurrence-free survival. Though the cohorts ana-
lyzed with qRT-PCR were of limited patient number
they are to date the largest series, in which EEF1A2
expression was profiled in PCa with a specific method.
Furthermore this is the first study correlating clinical
follow-up data with EEF1A2 expression in PCa.
Data on metastatic tumors has not been reported, yet.
By reanalyzing existing microarray data, we revealed
EEF1A2 to be overexpression in more than 50% of PCa
metastases, underlining its association with an aggressive
PCa phenotype.
Since EEF1A2 expression was not correlated with serum
PSA levels it might provide additional value in PCa risk
stratification of localized PCa as a tissue based marker, e.g.
from prostate biopsy samples. In this setting qRT-PCR
offers several advantages compared to conventional im-
munohistochemistry. qRT-PCR is more sensitive, allows a
better quantification and therefore contributes to a better
comparability between samples. Furthermore results are
less observer-dependent. However, qRT-PCR does not
give information about the expression pattern in the
tissue.
The results of the present study are in accordance with
results from the recent literature. Scaggiante et al. [21]
deemed EEF1A2 as a marker for prostate cell transform-
ation and a potential hallmark of cancer progression, since
they found it overexpressed in metastatic PCa cell lines,
compared with benign prostate cells. Additionally they
found it to be overexpressed both in PCa tissue and
peritumoral stroma in a small series of nine PCa patients.
Sun et al. [14] found a significantly higher RNA ex-
pression of EEF1A2 in 26 out of 30 primary PCa samples
compared to matched control samples. Using the same
a b
Fig. 4 a) EEF1A2 expression in the TCGA cohort (n = 499; dashed line indicated an expression z-score of 2). b) Tumors with an elevated EEF1A2
expression had a significantly shorter BCR-free survival
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cohort they could validate these results on the protein
level using immunohistochemistry. When they correlated
their immunohistochemistry results with clinical features
(age, PSA >/≤ 50 ng/ml, Gleason >/≤ 7, stages >/≤ T2),
they did not find a significant correlation. Unfortunately
they only performed these correlations on the protein
level and did not further stratify their cohort. Additionally
the number of patients in this study was comparably
small. Therefore a correlation of EEF1A2 expression and
the analyzed clinical features might have been missed.
They also did not implement any follow-up data, making
an outcome prediction impossible.
Reports on EEF1A2 expression in other tumor en-
tities show differing results. Interestingly some studies
attribute a higher expression of EEF1A2 with a poor
prognosis, whilst others found it to be associated with
a favorable outcome. In a large cohort of 438 primary
breast cancer specimen, absence of EEF1A2 protein
expression was a predictor of poor outcome [10].
EEF1A2 expression was not associated with other
established prediction markers like HER-2 protein ex-
pression, tumor size, lymph node status, and estrogen
receptor expression.
Controversially negative staining for EEF1A2 was a pre-
dictor for poor outcome in patients with non-small cell
lung cancer [22]. In pancreatic ductal adenocarcinoma el-
evated expression of EEF1A2 was associated with nodal
metastasis, perineural invasion and worse prognosis [11].
In vitro testing via siRNA-interference of EEF1A2 re-
vealed a reduction of PC3 cell migration, indicating a po-
tential tumor promoting function. Results on the impact
of EEF1A2 on PCa cell migration have not been reported
so far. The growth of PC3 cells was not altered. Interest-
ingly another study showed a significant reduction of
PCa cell growth and colony formation upon knockdown
of EEF1A2 [14], which is partly controversial to the find-
ings in the present study. Yet, differing results might be
caused by different assay conditions like the growth
media and siRNAs used.
A reduced growth of PCa cells upon EEF1A2 knock-
down is in line with the proposed pro-oncogenic func-
tion of EEF1A2 in PCa. The same study also found an
increase in apoptosis upon knockdown of EEF1A2,
which had already been described in studies on other
solid cancer entities [23, 24].
In pancreatic cancer EEF1A2 overexpression also re-
sulted in an activation of AKT and led to an overexpres-
sion of the matrixmetallo-protease MMP9, which is a key
player in extracellular matrix reorganization in context of
cancer progression [12].
a b
c
Fig. 5 In vitro testing of EEF1A2. a) qRT-PCR validation of siRNA-mediated knockdown of EEF1A2. b) EEF1A2 knockdown did not alter tumor cell
proliferation in PC3 cells, c) but significantly hampered PC3 cell migration in a scratch wound healing assay
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In hepatocellular carcinoma EEF1A2 was shown to
inactivate P53 via an upstream activation of the PI3K/
AKT/mTOR-pathway [25]. This gives rationale to a
druggability of EEF1A2-dependent tumor growth in PCa
with mTOR inhibitors, which are already in clinical use
e.g. for metastatic renal cell carcinoma, breast cancer,
neuroendocrine tumors and certain lymphomas [26, 27].
Actually, several early clinical trials using mTOR inhibi-
tors in metastatic PCa are ongoing but merely show
discouraging results [28–30]. A recent systematic review
suggested reciprocal feedback mechanisms between
PI3K and androgen receptor signaling to be causative
for this and proposed a combinatorial targeted therapy
of PI3K, mTOR and the androgen receptor [30].
Conclusion
qRT-PCR and in silico expression analyses confirm recent
reports from smaller series about EEF1A2 overexpression
in localized PCa. Furthermore this is the first study
describing EEF1A2 expression to be stage- and grade
dependent and EEF1A2 overexpression to be predictive
for the outcome of patients with localized PCa. Since
EEF1A2 expression is not correlated with serum PSA
levels, it might serve as an additional biomarker for PCa
risk stratification. Further prospective studies, investigat-
ing EEF1A2 expression e.g. in needle biopsy samples are
needed to evaluate its value as prognostic biomarker. In
vitro experiments give an outlook on the functional role
of EEF1A2 in PCa.
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